NEWS & MEDIA

Vitae Pharmaceuticals Hires Christine Brennan, Ph.D. as Chief Business Officer

Vitae Pharmaceuticals Receives $14 Million Milestone Payment as Boehringer Ingelheim Advances Lead Compound into Phase I Clinical Trials

Vitae Pharmaceuticals to Present at Windhover's Annual Therapeutic Area Partnerships Conference

Vitae Receives $8 Million Payment from Boehringer Ingelheim for Achievement of 11beta-HSD-1 Program Milestone

Vitae Initiates Phase 1 Trial of Novel Renin Inhibitor

Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration to research and develop novel treatments for Alzheimer's disease

Vitae Pharmaceuticals Secures $13 Million In Debt Financing

Vitae Pharmaceuticals Announces Promotion of Tina Fiumenero to Chief Financial Officer

Vitae Pharmaceuticals to Reacquire Full Rights to Renin Inhibitor Program For Hypertension

Vitae Pharmaceuticals Appoints Richard Gregg, M.D. as Chief Scientific Officer

Vitae Pharmaceuticals and Boehringer Ingelheim Announce a Major Collaboration to Develop and Commercialize Novel Treatments for Diabetes and Metabolic Diseases

Vitae Pharmaceuticals President John J. Baldwin Inducted into American Chemical Society Division of Medicinal Chemistry Hall of Fame

Vitae Pharmaceuticals Appoints Industry Veteran, Donald Hayden, as Chairman

Vitae Pharmaceuticals Secures $15 Million in Financing and Finalizes Renin Inhibitor Collaboration

Concurrent Pharmaceuticals Changes Name to Vitae Pharmaceuticals and Secures $34 Million in Financing: Company Evolves Strategic Focus to Advance Four Product Candidates

Concurrent Pharmaceuticals Appoints Jeffrey Hatfield as Chief Executive Officer

Concurrent Pharmaceuticals Announces $15 Million Private Financing, Collaboration With Intel and Rapid Progress On Renin Inihibitor Program

 

[back to top]

< Back to Home

Contact Us | Directions | Sitemap | Terms of Use

© 2007 Vitae Pharmaceuticals, Inc.

Vitae & Vitae Pharmaceuticals are trademarks of Vitae Pharmaceuticals, Inc.

design by Digizyme